Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Illumina (NASDAQ:ILMN - Get Free Report) posted its quarterly earnings data on Thursday. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05, RTT News reports. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company's revenue for the quarter was down 1.0% compared to the same quarter last year.

Illumina Trading Down 0.6 %

NASDAQ:ILMN traded down $0.69 on Thursday, reaching $123.99. The company's stock had a trading volume of 1,613,216 shares, compared to its average volume of 1,697,141. Illumina has a 12-month low of $89.00 and a 12-month high of $213.91. The stock has a 50 day moving average price of $130.57 and a 200 day moving average price of $127.14. The firm has a market cap of $19.75 billion, a price-to-earnings ratio of -16.99 and a beta of 1.20. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen bought 7,330 shares of the firm's stock in a transaction on Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.17% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating in a report on Tuesday, January 16th. OTR Global reissued a "mixed" rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. StockNews.com upgraded Illumina from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Finally, Stephens reissued an "overweight" rating and set a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.